A Phase IIb Study Testing ABP1011T Tablets for Treatment in Adults With Advanced Solid Tumors Including Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the efficacy and safety of ABP1011T tablets in participants with advanced solid tumors, including small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma. This open-label, multi-cohort Phase IIb study builds on prior safety and efficacy data from an earlier clinical trial. Priority enrollment is given to patients with small cell lung cancer who have failed at least two prior systemic therapies. Participants receive ABP1011T tablets orally once daily on an empty stomach with water, avoiding food for at least one hour before and after dosing. Treatment follows a continuous 21-day cycle, and the study includes multiple cohorts Cohort A focuses on small cell lung cancer patients, while Cohort B includes other advanced solid tumors. The study treatment is administered continuously throughout the trial. During the study, participants undergo regular assessments to monitor treatment effects and safety, including evaluations of tumor response using the objective response rate ORR over approximately two years. Secondary outcomes include duration of relief, progression-free survival, disease control rate, sustained response rate, overall survival, and treatment-related adverse events. Participants are monitored closely for up to two years to assess the impact of the study drug.

A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors